EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sendai virus, a candidate vaccine for the prevention of respiratory virus infections in children: a review

Bart G. Jones, Sherri L. Surman, Kristen Branum, Kim J. Allison, Toru Takimoto, Christopher Coleclough, Elisabeth E. Adderson, David I. Bernstein, Octavio Ramilo, Leena Yeolekar, Rajeev Dhere, Karen S. Slobod und 1 weitere

Frontiers in Microbiology · 16.11.2026 · 17

DOI: 10.3389/fmicb.2026.2002178 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 16.11.2026. Verfasst von Bart G. Jones und 12 weiteren Autor:innen. Die Arbeit nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Respiratory viruses including human parainfluenza virus (hPIV), respiratory syncytial virus (RSV), and human metapneumovirus (hMPV), pose serious, potentially lethal threats to humans, particularly infants and young children. While maternal vaccines and monoclonal antibodies are advancing to provide transient protection against these viruses, licensed pediatric vaccines are not yet available. Sendai virus (SeV) is now being developed as an intranasal (I.N.) vaccine candidate for the prevention of serious respiratory viral infections in children.

Methods

To examine the potential of replication-competent Sendai virus and its recombinants as pediatric respiratory virus vaccines against hPIV, RSV and hMPV, we searched literature databases and evaluated both historical and contemporary published research.

Results

SeV and SeV recombinant vaccines have been tested pre-clinically in a variety of animal models and in Phase I clinical studies. In pre-clinical models, a single dose of SeV induced rapid and long-lasting B- and T-cell responses in the upper respiratory tract and blood. When recombinant SeV constructs were produced and formulated into cocktail vaccines, they were protective against four different respiratory pathogens simultaneously. Vaccines were successful when partnered with passively transferred antibodies; specifically, when a recombinant SeV-based RSV vaccine was tested in the presence of passively transferred monoclonal or polyclonal PIV-specific or RSV-specific antibodies in a cotton rat model, the vaccine provided durable protective immunity against RSV. In clinical trials, SeV was well-tolerated and uniformly immunogenic in PIV-seropositive 1–2 year old children. Methods have been developed for the manufacture of stable SeV-based vaccine products, compatible with wide global distribution of SeV vaccines for clinical use.

Conclusion

To date, results highlight SeV as an attractive pediatric vaccine candidate. Continued clinical testing of SeV may provide global relief from serious respiratory viral infections in infants and young children.

Zitieren

APA

Jones, B. G., Surman, S. L., Branum, K., Allison, K. J., Takimoto, T., Coleclough, C., Adderson, E. E., Bernstein, D. I., Ramilo, O., Yeolekar, L., Dhere, R., Slobod, K. S., & Hurwitz, J. L. (2026). Sendai virus, a candidate vaccine for the prevention of respiratory virus infections in children: a review. Frontiers in Microbiology, 17. https://doi.org/10.3389/fmicb.2026.2002178

Vancouver

Jones BG, Surman SL, Branum K, Allison KJ, Takimoto T, Coleclough C, et al. Sendai virus, a candidate vaccine for the prevention of respiratory virus infections in children: a review. Frontiers in Microbiology. 2026;17. doi:10.3389/fmicb.2026.2002178

BibTeX
@article{Jones2026,
  author = {Jones, Bart G. and Surman, Sherri L. and Branum, Kristen and Allison, Kim J. and Takimoto, Toru and Coleclough, Christopher and Adderson, Elisabeth E. and Bernstein, David I. and Ramilo, Octavio and Yeolekar, Leena and Dhere, Rajeev and Slobod, Karen S. and Hurwitz, Julia L.},
  title = {Sendai virus, a candidate vaccine for the prevention of respiratory virus infections in children: a review},
  journal = {Frontiers in Microbiology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fmicb.2026.2002178}
}
Kostenlos starten →